La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Harvard Bioscience a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Harvard Bioscience..

Harvard Bioscience (NASDAQ:HBIO) Azioni, Catena delle Opzioni

Harvard Bioscience

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.

Harvard Bioscience Inc

Benchmark analyst Bruce Jackson maintains Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) with a Speculative Buy and lowers the price target from $5.5 to $4.5.

News

Price Target

Analyst Ratings

HBIO

Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $4.5

WIIM

Harvard Bioscience shares are trading lower. The company reported Q4 financial results.

Q1 2025 Guidance
Given the prevailing uncertainty in NIH funding and academic research purchasing, along with normal seasonality, the Company expects Q1 2025 revenues of $19 million to $21 million and gross margin in the 56% to 58% range.

Guidance

Harvard Bioscience Expects Q1 Revenue Of $19M-$21M Vs $22.95M Est

Earnings

Earnings Beats

Harvard Bioscience Q4 2024 Adj. EPS $0.06 Beats $0.05 Estimate, Sales $24.556M Beat $24.150M Estimate

<h3>Companies Reporting Before The Bell</h3>
• EHang Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>) is projected to report quarterly loss at $0.07 per share on revenue of $23.36 million. 
• Hello Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOMO#NASDAQ">MOMO</a>) is projected to report quarterly earnings at $0.21 per share on revenue of $365.05 million. 
• Chicago Atlantic Real (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFI#NASDAQ">REFI</a>) is estimated to report quarterly earnings at $0.56 per share on revenue of $14.19 million. 
• Waterdrop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDH#NYSE">WDH</a>) is expected to report earnings for its fourth quarter. 
• Upland Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPLD#NASDAQ">UPLD</a>) is projected to report quarterly earnings at $0.20 per share on revenue of $67.84 million. 
• VNET Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $284.88 million. 
• Vera Bradley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) is likely to report quarterly earnings at $0.06 per share on revenue of $107.94 million. 
• Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $200.59 million. 
• Arcos Dorados Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCO#NYSE">ARCO</a>) is likely to report quarterly earnings at $0.21 per share on revenue of $1.15 billion. 
• Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $194.15 million. 
• OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $30.36 million. 
• Navigator Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVGS#NYSE">NVGS</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $120.87 million. 
• ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) is projected to report quarterly earnings at $0.78 per share on revenue of $2.09 billion. 
• Smith Douglas Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDHC#NYSE">SDHC</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $265.85 million. 
• Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) is expected to report quarterly loss at $0.03 per share on revenue of $32.37 million. 
• ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) is expected to report quarterly earnings at $3.49 per share on revenue of $2.02 billion. 
• Solo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTC#NYSE">DTC</a>) is projected to report quarterly earnings at $0.13 per share on revenue of $161.60 million. 
• National Energy Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NESR#NASDAQ">NESR</a>) is estimated to report quarterly earnings at $0.25 per share on revenue of $339.84 million. 
• iRobot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) is expected to report quarterly loss at $1.73 per share on revenue of $171.00 million. 
• Ondas Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONDS#NASDAQ">ONDS</a>) is expected to report quarterly loss at $0.09 per share on revenue of $5.75 million. 
• BingEx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLX#NASDAQ">FLX</a>) is expected to report earnings for its fourth quarter. 
• InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) is likely to report quarterly loss at $0.19 per share on revenue of $1.82 million. 
• United Homes Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UHG#NASDAQ">UHG</a>) is estimated to report earnings for its fourth quarter. 
• Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $24.15 million. 
• MagnaChip Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MX#NYSE">MX</a>) is expected to report quarterly loss at $0.19 per share on revenue of $61.57 million. 
<h3>Companies Reporting After The Bell</h3>
• Vasta Platform (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTA#NASDAQ">VSTA</a>) is estimated to report quarterly earnings at $0.25 per share on revenue of $110.28 million. 
• KLX Energy Services Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLXE#NASDAQ">KLXE</a>) is expected to report quarterly loss at $0.80 per share on revenue of $168.90 million. 
• Algoma Steel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTL#NASDAQ">ASTL</a>) is expected to report earnings for its third quarter. 
• Comtech Telecom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) is projected to report quarterly loss at $0.25 per share on revenue of $129.53 million. 
• Aris Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARIS#NYSE">ARIS</a>) is estimated to report earnings for its fourth quarter. 
• Legacy Housing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGH#NASDAQ">LEGH</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $44.59 million. 
• Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) is expected to report quarterly loss at $0.19 per share on revenue of $36.66 million. 
• Montauk Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTK#NASDAQ">MNTK</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $56.32 million. 
• Ellington Credit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EARN#NYSE">EARN</a>) is expected to report quarterly earnings at $0.30 per share on revenue of $9.65 million. 
• FreightCar America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIL#NASDAQ">RAIL</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $152.02 million. 
• PHX Minerals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHX#NYSE">PHX</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $8.93 million. 
• Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) is expected to report quarterly earnings at $1.82 per share on revenue of $1.64 billion. 
• SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) is estimated to report quarterly loss at $0.21 per share on revenue of $222.33 million. 
• ContextLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) is likely to report earnings for its fourth quarter. 
• UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $425.34 million. 
• SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) is estimated to report quarterly loss at $1.50 per share on revenue of $710 thousand. 
• RCM Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCMT#NASDAQ">RCMT</a>) is expected to report quarterly earnings at $0.83 per share on revenue of $79.00 million. 
• Beauty Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKIN#NASDAQ">SKIN</a>) is projected to report quarterly loss at $0.09 per share on revenue of $77.45 million. 
• Fathom Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTHM#NASDAQ">FTHM</a>) is projected to report quarterly loss at $0.17 per share on revenue of $84.70 million. 
• Cardlytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDLX#NASDAQ">CDLX</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $63.63 million. 
• Biote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTMD#NASDAQ">BTMD</a>) is likely to report quarterly earnings at $0.17 per share on revenue of $51.20 million. 
• Limoneira (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMNR#NASDAQ">LMNR</a>) is projected to report quarterly loss at $0.17 per share on revenue of $40.70 million. 
• Calavo Growers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGW#NASDAQ">CVGW</a>) is expected to report quarterly earnings at $0.29 per share on revenue of $161.55 million. 
• KORU Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRMD#NASDAQ">KRMD</a>) is likely to report quarterly loss at $0.02 per share on revenue of $8.89 million. 
• American Eagle Outfitters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) is likely to report quarterly earnings at $0.51 per share on revenue of $1.60 billion. 
• Berry Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRY#NASDAQ">BRY</a>) is expected to report quarterly earnings at $0.15 per share on revenue of $173.00 million. 
• Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) is projected to report quarterly loss at $0.19 per share on revenue of $108.91 million. 
• Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) is projected to report quarterly earnings at $4.97 per share on revenue of $5.66 billion. 
• electroCore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECOR#NASDAQ">ECOR</a>) is expected to report quarterly loss at $0.34 per share on revenue of $7.29 million. 
• AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $9.73 million. 
• BGSF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGSF#NYSE">BGSF</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $67.65 million. 
• CI&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CINT#NYSE">CINT</a>) is projected to report earnings for its fourth quarter. 
• Companhia Siderurgica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SID#NYSE">SID</a>) is projected to report quarterly loss at $0.09 per share on revenue of $1.94 billion. 
• Performant Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHLT#NASDAQ">PHLT</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $34.15 million. 
• Urgently (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULY#NASDAQ">ULY</a>) is expected to report earnings for its fourth quarter. 
• Assertio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASRT#NASDAQ">ASRT</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $28.67 million. 
• Quest Resource Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRHC#NASDAQ">QRHC</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $73.63 million. 
• CPS Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPSH#NASDAQ">CPSH</a>) is estimated to report earnings for its fourth quarter. 
• Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>) is expected to report earnings for its third quarter. 
• Zedge (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZDGE#AMEX">ZDGE</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $7.71 million. 
• NextNav (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NN#NASDAQ">NN</a>) is expected to report quarterly loss at $0.14 per share on revenue of $1.73 million. 
• Monogram Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRM#NASDAQ">MGRM</a>) is estimated to report earnings for its fourth quarter. 
• Fossil Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOSL#NASDAQ">FOSL</a>) is likely to report earnings for its fourth quarter. 
• Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $29.00 million. 
• Aris Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMN#AMEX">ARMN</a>) is likely to report earnings for its fourth quarter. 
• Brilliant Earth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLT#NASDAQ">BRLT</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $116.82 million. 
• Tilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLYS#NYSE">TLYS</a>) is expected to report quarterly loss at $0.29 per share on revenue of $159.90 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADBE

AEYE

AMRN

ANIK

ARCO

ARIS

ARMN

ASRT

ASTL

BGSF

BRLT

BTMD

CDLX

CINT

CMTL

CPSH

CVGW

EARN

ECOR

FOSL

FTHM

IRBT

KEQU

KLXE

KRMD

LEGH

LMNR

LOGC

MGRM

MNTK

MOMO

NESR

NKTR

NSPR

NVGS

ONDS

OPRX

PATH

PHLT

QRHC

RAIL

RCMT

REFI

SDHC

SEAT

SKIN

SNES

TLYS

UPLD

VNET

VSTA

ZDGE

Earnings Scheduled For March 12, 2025

<h3>Gainers</h3>
<ul>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares moved upwards by 36.8% to $1.98 during Thursday's regular session. The market value of their outstanding shares is at $43.6 million. As per the news, the Q2 earnings report came out today. </li>
<li>Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) shares moved upwards by 31.25% to $0.95. The market value of their outstanding shares is at $109.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares increased by 30.76% to $12.03. The market value of their outstanding shares is at $630.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock increased by 29.17% to $0.71. The market value of their outstanding shares is at $10.6 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock rose 23.03% to $0.08. The market value of their outstanding shares is at $4.0 million. </li>
<li>Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) shares rose 19.61% to $5.0. The company's market cap stands at $151.1 million. As per the press release, Q3 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares fell 28.7% to $0.92 during Thursday's regular session. The company's market cap stands at $40.4 million. </li>
<li>Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) shares fell 24.69% to $18.06. The company's market cap stands at $3.6 billion. As per the news, the Q3 earnings report came out today. </li>
<li>Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) shares declined by 19.54% to $4.49. The market value of their outstanding shares is at $296.0 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Axogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXGN#NASDAQ">AXGN</a>) shares decreased by 17.75% to $12.61. The company's market cap stands at $552.6 million. The company's, Q3 earnings came out today. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) shares fell 17.56% to $2.33. The market value of their outstanding shares is at $101.3 million. As per the press release, Q3 earnings came out today. </li>
<li>Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) shares decreased by 16.41% to $3.64. The market value of their outstanding shares is at $1.8 billion. As per the press release, Q3 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AXGN

CELU

CHRS

CLOV

ENSC

PSNL

XRAY

12 Health Care Stocks Moving In Thursday's Intraday Session

Harvard Bioscience Sees Q4 Revenue $23M-$26M

Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.03 by 166.67 percent. The company reported quarterly sales of $22.000 million which missed the analyst consensus estimate of $25.300 million by 13.04 percent. This is a 13.26 percent decrease over sales of $25.363 million the same period last year.

Earnings Misses

Harvard Bioscience Q3 2024 Adj. EPS $(0.02) Misses $0.03 Estimate, Sales $22.000M Miss $25.300M Estimate

The Company expects 2024 full year gross margin of approximately&nbsp;59%&nbsp;to&nbsp;60%&nbsp;and adjusted EBITDA margin in the high single digits.

Harvard Bioscience Cuts FY24 Revenue Outlook To $97M - $102M ($111.95M), In Light Of Delayed Market Recovery (Prior Outlook: Flat Y/Y)

Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) reported quarterly earnings of $0.00 per share which missed the analyst consensus estimate of $0.05 by 98 percent. This is a 97.5 percent decrease over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $23.097 million which missed the analyst consensus estimate of $26.400 million by 12.51 percent. This is a 19.69 percent decrease over sales of $28.759 million the same period last year.

Harvard Bioscience Q2 2024 Adj. EPS $0.00 Misses $0.05 Estimate, Sales $23.097M Miss $26.400M Estimate

The Dow Jones index closed lower by around 0.2% on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Harvard Bioscience</h3>
<ul>
<li>The Trade: Harvard Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) CEO James W Green <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 10,000 shares</a> at an average price of $2.91. To acquire these shares, it cost around $29,100.</li>
<li>What's Happening: On May 7, Harvard Bioscience posted weaker-than-expected quarterly sales.</li>
<li>What Harvard Bioscience Does: Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development.</li>
</ul>
<h3 class="wp-block-heading">Sypris Solutions</h3>
<ul>
<li>The Trade: Sypris Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYPR#NASDAQ">SYPR</a>) Director Gary L Convis <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 20,000 shares at </a>an average price of $1.92. To acquire these shares, it cost around $38,400.</li>
<li>What's Happening: On June 3, Sypris named Michael D. Sedgwick as Vice President and General Manager of Sypris Electronics, LLC.</li>
<li>What Sypris Solutions Does: Sypris Solutions Inc is a USA-based company engaged in providing truck components, oil and gas pipeline components, and aerospace and defense electronics.</li>
</ul>
<h3 class="wp-block-heading">Holley</h3>
<ul>
<li>The Trade: Holley Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLLY#NYSE">HLLY</a>) Exec. Chairman of the Board Matthew E Rubel <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 14,493 shares</a> at an average price of $3.39. The insider spent around $49,131 to buy those shares. </li>
<li>What's Happening: On June 4, Telsey Advisory Group analyst Joseph Feldman maintained Holley with an Outperform and maintained a $6.5 price target.</li>
<li>What Holley Does: Holley Inc is a designer, marketer, and manufacturer of high-performance automotive aftermarket products, featuring a portfolio of iconic brands serving the car and truck industry.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/24/06/39331770/wall-streets-most-accurate-analysts-weigh-in-on-3-tech-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Tech Stocks With Over 3% Dividend Yields</a>

Long Ideas

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

HLLY

SYPR

Holley And 2 Other Stocks Under $5 Insiders Are Buying

The Dow Jones index closed lower by around 0.2% on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Harvard Bioscience</h3>
<ul>
<li>The Trade: Harvard Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) CEO James W Green <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 20,000 shares</a> at an average price of $3.07. To acquire these shares, it cost around $61,400.</li>
<li>What's Happening: On May 7, Harvard Bioscience posted weaker-than-expected quarterly sales.</li>
<li>What Harvard Bioscience Does: Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development.</li>
</ul>
<h3 class="wp-block-heading">EZFill Holdings</h3>
<ul>
<li>The Trade: EZFill Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZFL#NASDAQ">EZFL</a>) 10% owner Michael D Farkas <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 10,000 shares at</a> an average price of $2.10. To acquire these shares, it cost around $20,985.</li>
<li>What's Happening: On May 15, EzFill Holdings posted a narrower loss&nbsp; for the first quarter.</li>
<li>What EZFill Holdings Does: EzFill Holdings Inc is an application-based on-demand fuel delivery company in Florida and a mobile fueling company that combines on-demand fills and subscription services that fill customer vehicles on routine intervals.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/06/39226661/top-4-tech-stocks-that-may-explode-this-month">Top 4 Tech Stocks That May Explode This Month</a>
<h3 class="wp-block-heading">Air Industries Group</h3>
<ul>
<li>The Trade: Air Industries Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIRI#NYSE">AIRI</a>) President Luciano M Melluzzo <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 11,082 shares</a> at an average price of $3.64. The insider spent around $40,283 to buy those shares. </li>
<li>What's Happening: On May 15, Air Industries Group reported better-than-expected first-quarter sales results.</li>
<li>What Air Industries Group Does: Air Industries Group is an aerospace and defense company.</li>
</ul>
<h3 class="wp-block-heading">FlexShopper</h3>
<ul>
<li>The Trade: FlexShopper, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FPAY#NASDAQ">FPAY</a>) Director Howard Dvorkin <a href="https://www.benzinga.com/quote/FPAY/analyst-ratings">acquired a total of 75,346 shares</a> at an average price of $1.10. The insider spent around $83,112 to buy those shares.</li>
<li>What's Happening: On May 13, FlexShopper posted upbeat quarterly sales.</li>
<li>What FlexShopper Does: FlexShopper Inc is a financial technology company engaged in providing certain types of durable goods to consumers on a lease-to-own basis and providing lease-to-own (LTO) terms to consumers of third-party retailers and e-tailers.</li>
</ul>
Don&#8217;t forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>

AIRI

EZFL

FPAY

FlexShopper And 3 Other Stocks Under $5 Insiders Are Buying

For the full year 2024 revenues to be approximately flat versus 2023. Company sees second half growth versus both first half of 2024 and second half of 2023, supported by new product commercializations and expected improvements in China. The company seest 2024 gross margin of approximately 60% and adjusted EBITDA margin in the mid-teens.

Harvard Bioscience Continues To Expect 2024 Gross Margin Of Approximately 60% And Adjusted EBITDA Margin In The Mid-teens

Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) reported quarterly earnings of $0.02 per share which met the analyst consensus estimate. This is a 66.67 percent decrease over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $24.51 million which missed the analyst consensus estimate of $25.79 million by 4.96 percent. This is a 18.23 percent decrease over sales of $29.98 million the same period last year.

Harvard Bioscience Q1 Adj $0.02, Inline, Sales $24.51M Miss $25.79M Estimate

Harvard Bioscience Expects Overall Run Rate Savings Of ~$4M Beginning In Q2 2024; Expects Q2 Restructuring-Related Charges Of ~$0.5M

Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) reported quarterly earnings of Adj $0.04 per share which missed the analyst consensus estimate of $0.05 by 20 percent. This is unchanged from the same period last year. The company reported quarterly sales of $28.15 million which missed the analyst consensus estimate of $29.11 million by 3.29 percent. This is a 0.96 percent decrease over sales of $28.43 million the same period last year.

Harvard Bioscience Q4 Adj EPS $0.04 Misses $0.05 Estimate, Sales $28.15M Miss $29.11M Estimate

AFCG

ALIM

AMTX

AOUT

ARBE

ARCT

ARHS

ASLE

ASPS

AVGO

BBAI

BBCP

BILI

BITF

BNED

BURL

CHMI

CIEN

CLAR

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

COOK

COST

CTOS

DBVT

DLTH

DOCU

DOMO

DSGR

DXPE

ELUT

EOLS

EVGN

EYPT

FCEL

FNKO

GEVO

GIFI

GRND

GRNT

GWRE

ISDR

JYNT

LCTX

LOCO

LUMO

LVRO

METC

MGNX

MKFG

MRVL

NAPA

NCSM

NDLS

NEPH

NINE

ONCT

ONCY

OPFI

OPTN

OWLT

PBPB

PHAT

PMTS

PRCH

PowerShares Dynamic Industrials Sector Portfolio

PROF

PRTS

PSFE

RDVT

REAX

REFR

RWAY

SDPI

SGHT

Earnings Scheduled For March 7, 2024

Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) is set to give its latest quarterly earnings report on Thursday, 2024-03-07. Here's what investors need to know before the announcement.
Analysts estimate that Harvard Bioscience will report an earnings per share (EPS) of $0.05. 
Harvard Bioscience bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.03, which was followed by a 1.41% drop in the share price the next day.
Here's a look at Harvard Bioscience's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.04</td>
<td>0.05</td>
<td>0.05</td>
<td>0.03</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.01</td>
<td>0.04</td>
<td>0.06</td>
<td>0.04</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-2.0%</td>
<td>6.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709755299_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Harvard Bioscience were trading at $4.19 as of March 05. Over the last 52-week period, shares are up 60.9%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/HBIO/earnings">To track all earnings releases for Harvard Bioscience visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of Harvard Bioscience's Earnings

Harvard Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) today announced that it will be showcasing its latest product innovations at the Society of Toxicology (SOT) conference from March 11-13, 2024, in Salt Lake City. Complementing an already extensive product line, the new innovations provide exciting new opportunities for advancing preclinical and organoid-focused therapy development.
DSI&#x2122; Ponemah&#x2122; Data Management Platform Provides Integrated Preclinical Solution
The Company's industry-leading GLP-compliant Ponemah&#x2122; preclinical data management platform now includes integrations with the new SoHo&#x2122; implantable telemetry solution and the VivaMARS&#x2122; high-capacity behavior monitoring system.
By integrating these new applications in a single data management platform, the Ponemah system provides users with a powerful tool for managing and analyzing data across a range of studies. The integrated platform also opens new opportunities for the use of emerging machine learning-based algorithms to efficiently analyze large data pools.
SoHo&#x2122; Implantable Real-Time Telemetry for Small Animal Models
Together with the Ponemah platform, the SoHo telemetry solution enables researchers to collect, manage, analyze and report findings from multiple concurrent small animal models in a more natural shared housing environment. In addition, the SoHo solution allows data to be collected over longer time periods and opens exciting new opportunities for longitudinal studies. SoHo supports the customer's business needs by reducing operating costs and test cycle times, enabling increased testing throughput. For more information visit the DSI website at <a href="https://www.globenewswire.com/Tracker?data=V8ttPoHOw-EWSx9Um07ZYwe5VlppD0o8MJ4X2v5N4thoMRS7kenOSrZex0VFi96EA6yM8NDG-PafowI5SJp-3OtHBoLUu0RK2iXHGbpjsbNVjg-nfLZ0vqi6dFm4XZxEvouSUL8oBEwZFXR38dntXueYlATD9BM14JC0frFcJI4-NSS2jPfQQvxzQEGG2lTyUIHX1gUNz2aFXB4bUbqsxJ6z3YO5XdIhOn4UeSm7rNE=">https://www.datasci.com/products/implantable-telemetry/soho-telemetry-system</a>.
VivaMARS&#x2122; Activity Monitoring System
The VivaMARS system combines the Company's infrared Panlab&#xAE; activity monitoring technology with its Ponemah platform to create an integrated, GLP-compliant solution for real-time, high precision behavioral testing. The system is ideally suited to meet the high throughput, automated neuropharmacology and neurotoxicology testing needs of CROs and pharma companies, in addition to longitudinal behavior studies carried out by leading research and academic institutes. For more information on the VivaMARS system, visit the DSI website at&nbsp;<a href="https://www.globenewswire.com/Tracker?data=V8ttPoHOw-EWSx9Um07ZYwe5VlppD0o8MJ4X2v5N4tgnf4OLdDHWo1EVNiwqhpgG9wIRACGAhPJeJgbGe7__G-8MikHmP8Fplwo9hIfJaqcQuvuRqDwZH0y4vLCKztBqthAsA61bf7X6sAEn2iTiDN2Ht1gN2NAhN2HswodVQj5nXZEUpCy9hXUxBMg9QDSFMgU1srjZyIcatryzSvcrPQ6sPO05il-x28H_EowzV5SP-2OmL7kC7azRdUJytqF0G-mhE06sGQQ7WhL8gU3Gu1sHdc92iW3I9mUKmfpMonmHbghXRfqX_7_k1GugB8belenv_OWs1VIbmNOYHBInSNA7je09iOIHOnOkpxE8XFzt3ZmF6JGZXL_zJkl-ud2tGKhX7K6mZskXT1uf_y10rerFhRNKxs__6uZP1Y6F2eQWMXg15uOsnewwTJ3Kckrlxi14DH9wMEKmddAesUdWY6eEV547whTKIt9oAQ_7AlfWOcQ5lh9QVna6e1F8VGVuUIyEAsTkgmNb_Q8tsbLOT_rYcr0QxToA_vB8K8DGIBE=">https://www.datasci.com/products/behavior/vivamars-mobile-activity-rack-system</a>.
MCS&#x2122; Mesh MEA&#x2122; Organoid Platform
The Company will also exhibit its new organoid-centric mesh Microelectrode Array (MEA) platform. Expanding on its recognized leadership position in&nbsp;in-vitro&nbsp;MEA products, the new Mesh MEA&#x2122; platform allows researchers to capture precise electrophysiology measurements from inside the living organoid in real time. The new Mesh MEA platform is designed for the emerging applications of organoids in research and discovery, safety pharmacology and toxicology. For more information on our mesh MEA products and organoid research, visit our website at&nbsp;<a href="https://www.globenewswire.com/Tracker?data=V8ttPoHOw-EWSx9Um07ZY0iuEan2Nwz07whRvDUdm_kW3beeznFV1znI6_gTvOh8nPMNBCi7hBm9WehQMZsDeO35Xn1fUycFeUy3Iv2CC_GU-gn3kLGkjQhYRf__qmRKVAfy7Ce1gpF3ho_RaBmDGBTopt7ArTeO5niLrZ8mxSoUAFyHjBE1yzbb9Pvqo1oRVYJPvJO-xs1o9rgSP9oWAGmutXqxsTKU6ZTpxHZynJjUd2s6vE1vjhxolRUm4bKPuT-BF3EOYBmBa1YgwIFju-sphUvfbnyZhCQJX6KW8NtHBZ-QCeBosw8qI_8Y7nwH997PukKWrfzyJ_Pext5o-l3EMzMaerdDkPu--TN3ETXM8hfyuCTb6Wmhncy_8lg3yDPFDXBDxlUUara_QRaXobWffyPUb35S3ikhJ1_ekoepjvWUaDPakqiWX1lXpXkruEOiz0PjGVty_1u_6qjFtA==">https://www.harvardbioscience.com/applications/organoid-research</a>.
Solutions for New Therapy Development
Jim Green, Harvard Bioscience Chairman and CEO, said, "We are pleased to offer our CRO, pharma, and biotech customers innovative products designed to reduce cycle times, improve throughput, and reduce time to market. Looking to the future, I'm especially excited by the potential of our Ponemah platform to advance the use of emerging artificial intelligence (AI) and machine learning technologies to streamline data analysis and reporting in applications such as toxicology and organoid testing."
Serge Savard, Harvard Bioscience Vice President of Product Management, said, "By integrating these new applications in a single data management platform, our Ponemah system provides a proven solution for preclinical testing. And, with the emergence of new machine learning technologies and their potential to automate the analysis and review of large data sets, we are already starting to receive customer interest in extending the Ponemah platform to incorporate these technologies."
Booth at Society of Toxicology
The Company will be exhibiting a range of solutions at Society of Toxicology booth #2304, at the Salt Palace Convention Center (Salt Lake City, UT). Representatives will be present during exhibit hours from Monday, March 11, 2024 through Wednesday, March 13, 2024.

Biotech

General

Harvard Bioscience To Showcase Latest Solutions For Preclinical And Organoid Applications At Society Of Toxicology Meeting

Health Care

Considering Headwinds In Asia, Harvard Bioscience Expects FY23 Revenue To Be Approximately Flat As Compared To 2022 Versus $116M-$120M Expected Earlier And Consensus Of $116.95M

Press Releases

Harvard Bioscience to Showcase Innovative Technologies at Society for Neuroscience (SfN) Annual Meeting 2024

Harvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET

Harvard Bioscience Announces Third Quarter 2024 Financial Results

Comments

Harvard Bioscience

Harvard Bioscience (HBIO) Opzioni

Harvard Bioscience (NASDAQ:HBIO) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO